Clarivate (NYSE:CLVT) Raised to “Buy” at Wall Street Zen

Clarivate (NYSE:CLVT) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

A number of other equities analysts have also recently commented on CLVT. Citigroup decreased their target price on Clarivate from $4.25 to $2.80 and set a “neutral” rating on the stock in a report on Wednesday, March 4th. The Goldman Sachs Group cut Clarivate from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $4.20 to $3.60 in a report on Thursday, January 8th. Royal Bank Of Canada decreased their target price on shares of Clarivate from $5.00 to $3.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Clarivate in a report on Friday, March 27th. Finally, Barclays lowered their price target on shares of Clarivate from $4.00 to $2.40 and set an “underweight” rating on the stock in a report on Wednesday, February 25th. Five analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and an average target price of $3.22.

Clarivate Stock Performance

CLVT opened at $2.79 on Friday. Clarivate has a 12-month low of $1.66 and a 12-month high of $4.77. The company’s 50 day moving average is $2.47 and its 200 day moving average is $2.94. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -13.26 and a beta of 1.41. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 0.89.

Clarivate (NYSE:CLVT) last announced its earnings results on Wednesday, April 29th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. Clarivate had a positive return on equity of 8.82% and a negative net margin of 5.61%.The company had revenue of $585.50 million for the quarter, compared to analysts’ expectations of $569.50 million. During the same period last year, the firm earned $0.14 EPS. Clarivate’s revenue for the quarter was down 1.4% compared to the same quarter last year. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. On average, equities research analysts predict that Clarivate will post 0.63 EPS for the current year.

Hedge Funds Weigh In On Clarivate

Several large investors have recently added to or reduced their stakes in the company. Cetera Investment Advisers lifted its holdings in Clarivate by 11.2% during the second quarter. Cetera Investment Advisers now owns 26,034 shares of the company’s stock valued at $112,000 after purchasing an additional 2,617 shares in the last quarter. California State Teachers Retirement System lifted its holdings in Clarivate by 0.9% during the second quarter. California State Teachers Retirement System now owns 303,147 shares of the company’s stock valued at $1,304,000 after purchasing an additional 2,788 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Clarivate by 3.9% during the third quarter. Envestnet Asset Management Inc. now owns 77,275 shares of the company’s stock valued at $296,000 after buying an additional 2,884 shares during the last quarter. IFP Advisors Inc raised its position in shares of Clarivate by 8.1% during the third quarter. IFP Advisors Inc now owns 41,426 shares of the company’s stock valued at $170,000 after buying an additional 3,117 shares during the last quarter. Finally, Hsbc Holdings PLC raised its position in shares of Clarivate by 4.3% during the second quarter. Hsbc Holdings PLC now owns 116,648 shares of the company’s stock valued at $500,000 after buying an additional 4,792 shares during the last quarter. Hedge funds and other institutional investors own 85.72% of the company’s stock.

Clarivate Company Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.